SLS Stock Hits Over 5-Year High as Retail Traders Bet $25; AML Trial Nears 80-Event Milestone

According to Stocktwits data, SLS stock hit a more-than-five-year high on Monday (June 29), closing at $15.45, up 25% in a single session, as the company's Phase 3 Regal trial for acute myeloid leukemia reached 78 of 80 required events needed for final analysis. CEO Angelos Stergiou called the slower event accumulation a positive signal, stating that patients may be living longer than expected.

A Stocktwits poll of about 3,600 voters showed 74% expect SLS to reach $25 or higher within 12 months, implying over 60% upside from current levels. Retail sentiment on the platform jumped to "extremely bullish" from "bullish" a week ago, with message volumes surging 600% in 24 hours.